Here’s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now

Merck’s inclusion among undervalued counter-cyclical stocks arrives at a pivotal moment for both the healthcare sector and the broader market. Counter-cyclical stocks—those that tend to outperform when economic conditions weaken—are gaining renewed attention as investors brace for potential volatility in late 2026. Healthcare, particularly pharmaceuticals, has long been a defensive play due to the inelastic demand for essential medicines and treatments, but Merck’s positioning goes beyond typical sector resilience. Its pipeline, anchored by a robust portfolio of oncology drugs and vaccines, offers a hedge against economic downturns while maintaining growth potential through innovation. What may surprise casual observers is Merck’s strategic pivot toward high-margin specialty drugs, even as it continues to benefit from legacy revenue streams. Over the past five years, the company has aggressively expanded its immunotherapy and antiviral portfolios, reducing reliance on traditional blockbusters that face patent cliffs. This transition not only insulates Merck from generic competition but also aligns with a broader industry trend: the shift toward targeted therapies that command premium pricing, regardless of macroeconomic conditions. Investors should note, however, that this shift introduces execution risk—delays in FDA approvals or clinical trial setbacks could undermine its counter-cyclical appeal. Looking ahead, the key question is whether Merck can sustain its valuation rebound amid evolving regulatory scrutiny and pricing pressures. The FDA’s recent actions on drug approvals—particularly for oncology treatments—suggest a more rigorous review process, which could slow new revenue infusions. Meanwhile, the looming 2026 U.S. election introduces political uncertainty, as drug pricing remains a contentious campaign issue. If lawmakers revive proposals to cap Medicare drug costs, Merck’s pricing power could face headwinds, even in a recessionary environment. For now, Merck’s valuation appears anchored by its defensive attributes, but the interplay between policy risks and innovation timelines will determine whether its counter-cyclical status is temporary or enduring.